DEXCOM INC
DXCMNASDAQTrading Snapshot
- Day Range
- $77.69 – $79.41
- 52-Week Range
- $54.11 – $92.59
- Volume (shares)
- 5,370,036
- Avg Volume (shares)
- —
- Shares Outstanding
- 377.4M
- Next Earnings
- 2027-02-10
Fundamentals Snapshot
- Annual Revenue
- $4.66B
- Last Q Revenue
- $1.31B
- P/E Ratio
- 30.4
- P/S Ratio
- 6.0x
- EPS (TTM)
- $2.61
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −1.9%
DEXCOM INC
DXCM
StockOtter · stockotter.spaceAbout DEXCOM INC
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p
DexCom Gears Up to Report Q3 Results: How to Play the Stock?
DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.
DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors
On October 21, 2026, DexCom Inc (DXCM) shares fell 6.4% to a current price of $80.26. This decline comes amidst a 52-week range of $54.11 to $92.59, highlightin
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares of Company Stock
DexCom, Inc. (NASDAQ: DXCM - Get Free Report) EVP Michael Brown sold 1,700 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value